Filing search / Ownership / Iovance Biotherapeutics, Inc. / Page 3

UPLOAD

dshegmpuy7g4r

26 Oct 23

Letter from SEC

12:00am

8-K

hsqxi0f3vy i4en21

15 Sep 23

U.S. Food and Drug Administration Updates

8:17am

8-K

ttqd31eyszhu

18 Aug 23

Regulation FD Disclosure

5:16pm

8-K

vyo9a875s0hlz

8 Aug 23

Iovance Biotherapeutics Reports Second Quarter and First Half 2023

4:05pm

8-K

rbysj

13 Jul 23

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

4:31pm

424B5

a6n5r979

11 Jul 23

Prospectus supplement for primary offering

5:08pm

8-K

yyqo45xm8uh5

11 Jul 23

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:55pm

424B5

za3 ugog1

10 Jul 23

Prospectus supplement for primary offering

5:27pm

8-K

9qqp83d j2g1w7jxaoi

10 Jul 23

Results of Operations and Financial Condition

4:40pm

8-K

gh2ve4

10 Jul 23

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

8:53am

8-K

iadu2hxbf5fzqenixc

16 Jun 23

Entry into a Material Definitive Agreement

4:51pm

424B5

u6cxueb1

16 Jun 23

Prospectus supplement for primary offering

4:39pm

S-3ASR

hlq5atp

16 Jun 23

Automatic shelf registration

4:11pm

S-8

8qlxkzu3ihvcsobx0h

12 Jun 23

Registration of securities for employees

4:31pm

S-8

2sh4kwhh ozgd

12 Jun 23

Registration of securities for employees

4:30pm

8-K

wybcbgj uuhn9cgz330i

6 Jun 23

Submission of Matters to a Vote of Security Holders

5:17pm

8-K/A

nbi2rcy6fslls

2 Jun 23

Financial Statements and Exhibits

4:30pm

8-K

0gl58ee8i5wji

26 May 23

Iovance Biotherapeutics Announces U.S. Food and Drug Administration

8:38pm

8-K

zck9udn0w

18 May 23

Completion of Acquisition or Disposition of Assets

4:30pm